John G Ullman & Associates Inc. Sells 17,926 Shares of Pfizer Inc. (NYSE:PFE)

John G Ullman & Associates Inc. lessened its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 6.4% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 261,167 shares of the biopharmaceutical company's stock after selling 17,926 shares during the quarter. Pfizer accounts for about 1.0% of John G Ullman & Associates Inc.'s investment portfolio, making the stock its 27th largest holding. John G Ullman & Associates Inc.'s holdings in Pfizer were worth $6,618,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. Avantax Advisory Services Inc. boosted its stake in shares of Pfizer by 5.9% during the 1st quarter. Avantax Advisory Services Inc. now owns 369,411 shares of the biopharmaceutical company's stock valued at $9,361,000 after buying an additional 20,421 shares during the last quarter. Hamilton Point Investment Advisors LLC increased its position in Pfizer by 18.5% in the first quarter. Hamilton Point Investment Advisors LLC now owns 175,596 shares of the biopharmaceutical company's stock worth $4,450,000 after buying an additional 27,431 shares during the period. Brookwood Investment Group LLC acquired a new stake in Pfizer in the first quarter worth $227,000. Jackson Hole Capital Partners LLC increased its holdings in shares of Pfizer by 11.9% during the first quarter. Jackson Hole Capital Partners LLC now owns 110,837 shares of the biopharmaceutical company's stock valued at $2,809,000 after purchasing an additional 11,828 shares during the period. Finally, Lincluden Management Ltd. increased its holdings in shares of Pfizer by 7.7% during the first quarter. Lincluden Management Ltd. now owns 415,454 shares of the biopharmaceutical company's stock valued at $10,528,000 after purchasing an additional 29,617 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on PFE shares. The Goldman Sachs Group raised their target price on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Wolfe Research raised their price objective on Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a research report on Wednesday, April 30th. Berenberg Bank cut their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. HSBC cut their price objective on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Finally, UBS Group lifted their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $28.55.

Pfizer Price Performance

PFE traded down $0.57 during trading on Friday, hitting $24.79. The company's stock had a trading volume of 35,628,980 shares, compared to its average volume of 38,205,096. The firm's 50 day moving average price is $24.30 and its two-hundred day moving average price is $24.68. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The stock has a market capitalization of $140.91 billion, a price-to-earnings ratio of 17.96, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm's quarterly revenue was down 7.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.82 earnings per share. Sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.94%. Pfizer's dividend payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.